High Growth Tech Stocks To Explore In November 2024

In this article:

Over the last 7 days, the United States market has dropped 2.1%, yet it remains up 30% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these positive earnings forecasts can be a strategic approach for those looking to explore opportunities in November 2024.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Invivyd

54.76%

71.32%

★★★★★★

Sarepta Therapeutics

23.89%

42.65%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Clene

78.50%

60.70%

★★★★★★

TG Therapeutics

34.66%

56.48%

★★★★★★

Travere Therapeutics

31.75%

72.43%

★★★★★★

Blueprint Medicines

25.47%

68.62%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Ardelyx

Simply Wall St Growth Rating: ★★★★★☆

Overview: Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for gastrointestinal and cardiorenal therapeutic areas globally, with a market cap of approximately $1.18 billion.

Operations: Ardelyx operates in the biopharmaceutical sector, focusing on the development and commercialization of treatments for gastrointestinal and cardiorenal conditions. The company's revenue is primarily derived from its biopharmaceutical products, amounting to $251.85 million.

Ardelyx, Inc., a biotech firm specializing in novel treatments for kidney and cardiovascular diseases, has shown a notable uptick in revenue, with a 25.6% annual growth rate that surpasses the US market average of 8.9%. Despite currently being unprofitable, Ardelyx's strategic focus on R&D is evident from its recent clinical advancements with XPHOZAH®, a pioneering treatment for hyperphosphatemia in dialysis patients. This product differentiation emphasizes Ardelyx’s commitment to addressing unmet medical needs, which may bolster its financial trajectory as earnings are projected to surge by approximately 69.6% annually. Moreover, the company's recent filing for a $167.865 million shelf registration suggests plans for capitalizing on these innovations to potentially fuel further growth and profitability within the next three years.

NasdaqGM:ARDX Earnings and Revenue Growth as at Nov 2024
NasdaqGM:ARDX Earnings and Revenue Growth as at Nov 2024

National CineMedia

Simply Wall St Growth Rating: ★★★★☆☆